News
ONCO
1.110
+7.77%
0.080
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 3d ago
5 Biotech Stocks Making Headlines - ADRX, CNSY, JAGX, AGL, ONCO
NASDAQ · 3d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 3d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 3d ago
Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Benzinga · 3d ago
SRX Global Liquidates 2 Portfolio Investments, Adds Onconetix Ahead Of Realbotix Deal
NASDAQ · 3d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 4d ago
SRX Global says adds investment in Onconetix
TipRanks · 4d ago
Weekly Report: what happened at ONCO last week (0914-0918)?
Weekly Report · 09/21 10:06
Onconetix Provides Up To $5 Mln Bridge Financing To Realbotix
NASDAQ · 09/15 13:14
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 09/14 17:06
Onconetix Secures Bridge Financing for Realbotix Acquisition
TipRanks · 09/14 15:17
Realbotix announces bridge loan from Onconetix
TipRanks · 09/14 11:45
Weekly Report: what happened at ONCO last week (0907-0911)?
Weekly Report · 09/14 10:10
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 09/08 21:06
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 09/08 12:05
Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
Benzinga · 09/08 08:44
Weekly Report: what happened at ONCO last week (0831-0904)?
Weekly Report · 09/07 10:05
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 09/04 21:06
Onconetix Acquisition Target Realbotix Launches European Telecom Robot Pilot
NASDAQ · 09/03 16:12
More
Webull provides a variety of real-time ONCO stock news. You can receive the latest news about Onconetix through multiple platforms. This information may help you make smarter investment decisions.
About ONCO
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.